方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 抑郁症状快速评估量表 (QIDS)× | Montgomery-Åsberg抑郁评定量表 (MADRS)× | |
|---|---|---|
| 领域 | 临床心理学 | 临床心理学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 2003 | 1979 |
| 提出者≠ | A. John Rush | Stuart Montgomery & Marie Åsberg |
| 类型≠ | Self-report or clinician-administered questionnaire | Clinician-rated interview scale |
| 开创性文献≠ | Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., & Ninan, P. T. (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583. DOI ↗ | Montgomery, S. A., & Åsberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382–389. DOI ↗ |
| 别名≠ | QIDS, Quick Inventory of Depressive Symptomatology-Self Report, QIDS-SR | MADRS, Montgomery-Asberg Depression Rating Scale |
| 相关≠ | 4 | 5 |
| 摘要≠ | The Quick Inventory of Depressive Symptomatology is a 16-item assessment designed by A. John Rush and colleagues to efficiently measure the severity of depressive symptoms in adults. Published in Biological Psychiatry in 2003, the QIDS exists in both self-report (QIDS-SR) and clinician-rated (QIDS-C) versions. It was developed as a brief alternative to the longer Inventory of Depressive Symptomatology (IDS, 30 items) while maintaining comprehensive coverage of DSM-IV depressive symptoms. The QIDS has become a standard outcome measure in treatment research, particularly in large comparative effectiveness trials. | The Montgomery-Åsberg Depression Rating Scale is a 10-item clinician-rated assessment designed by Stuart Montgomery and Marie Åsberg in 1979 to measure depression severity and track treatment response. Published in the British Journal of Psychiatry, the MADRS was developed as an alternative to longer instruments like the Hamilton Depression Rating Scale, emphasizing items most sensitive to treatment change. It has become a primary outcome measure in antidepressant trials and is widely used in both research and clinical practice across psychiatry, primary care, and medical specialty settings. |
| ScholarGate数据集 ↗ |
|
|